1 May 2025 in Diabetes & Metabolism Journal
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as blockbuster drugs for treating metabolic diseases. Glucagon-like peptide-1 (GLP-1) plays a pivotal role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and acting on the central nervous system to regulate satiation and satiety. This review summarizes the discovery of GLP-1 and the development of GLP-1RAs, with a particular focus on their central mechanisms of action. Human neuroimaging studies demonstrate that GLP-1RAs influence brain activity during food cognition, supporting a role in pre-ingestive satiation. Animal studies on hypothalamic feed-forward regulation of hunger suggest that cognitive hypothalamic mechanisms may also contribute to satiation control. We highlight the brain mechanisms of GLP-1RA-induced satiation and satiety, including cognitive impacts, with an emphasis on animal studies of hypothalamic glucagon-like peptide-1 receptor (GLP-1R) and GLP-1R-expressing neurons. Actions in non-hypothalamic regions are also discussed. Additionally, we review emerging combination drugs and oral GLP-1RA formulations aimed at improving efficacy and patient adherence. In conclusion, the dorsomedial hypothalamus (DMH)—a key GLP-1RA target—mediates pre-ingestive cognitive satiation, while other hypothalamic GLP-1R neurons regulate diverse aspects of feeding behavior, offering potential therapeutic targets for obesity treatment.
17 March 2023 in Nature Communications
For survival, it is crucial for eating behaviours to be sequenced through two distinct seeking and consummatory phases. Heterogeneous lateral hypothalamus (LH) neurons are known to regulate motivated behaviours, yet which subpopulation drives food seeking and consummatory behaviours have not been fully addressed. Here, in male mice, fibre photometry recordings demonstrated that LH leptin receptor (LepR) neurons are correlated explicitly in both voluntary seeking and consummatory behaviours. Further, micro-endoscope recording of the LHLepR neurons demonstrated that one subpopulation is time-locked to seeking behaviours and the other subpopulation time-locked to consummatory behaviours. Seeking or consummatory phase specific paradigm revealed that activation of LHLepR neurons promotes seeking or consummatory behaviours and inhibition of LHLepR neurons reduces consummatory behaviours. The activity of LHLepR neurons was increased via Neuropeptide Y (NPY) which acted as a tonic permissive gate signal. Our results identify neural populations that mediate seeking and consummatory behaviours and may lead to therapeutic targets for maladaptive food seeking and consummatory behaviours.
8 November 2024 in Science Advances
Physiological needs evoke motivational drives that produce natural behaviors for survival. In previous studies, the temporally intertwined dynamics of need and motivation have made it challenging to differentiate these two components. On the basis of classic homeostatic theories, we established a normative framework to derive computational models for need-encoding and motivation-encoding neurons. By combining the model-based predictions and naturalistic experimental paradigms, we demonstrated that agouti-related peptide (AgRP) and lateral hypothalamic leptin receptor (LH LepR) neuronal activities encode need and motivation, respectively. Our model further explains the difference in the dynamics of appetitive behaviors induced by optogenetic stimulation of AgRP or LH LepR neurons. Our study provides a normative modeling framework that explains how hypothalamic neurons separately encode need and motivation in the mammalian brain.
31 August 2025 in Annals of Pediatric Endocrinology & Metabolism
Ever since its discovery, glucagon-like-peptide 1 (GLP-1) and drugs with similar function (collectively GLP-1s) have been used for type 2 diabetes mellitus and have been effective for obesity. Their profound effect on weight loss has resulted in widespread use of these medicines for treating obesity. Extensive studies have shown that GLP-1s decrease body weight, lean mass, and other metabolic phenotypes. These studies were supported by the mechanism of signaling pathways of GLP-1s in cells and their metabolic effects. Recently, studies have focused on the effect of GLP-1s on the brain, showing that they affect food cognition, depression, drug addiction, and even neurodegenerative diseases. Although recent studies have investigated the impact of GLP-1s on the brain, our understanding of these effects is limited. This review describes how GLP-1s have become the most effective drugs in obesity, such as their known signaling pathway in cells and their pharmaceutical processing over the years. This review covers recent discoveries of the GLP-1 mechanisms in the brain, including their prominent effects on obesity, and discusses discoveries that imply their potential usage in brain disorders.